Email Updates

You are here

AVAC in the News

  • The new World Health Organization (WHO) guidelines on HIV treatment and prevention which were released at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur do provide hope that more people living with HIV will be able to live healthy - only if these guidelines get implemented in letter and spirit on the ground.

    July 3, 2013
    Asian Tribune
  • A trial of the only vaccine to offer partial protection from HIV, after 30 years of research, was started in South Africa this week.

    June 21, 2013
    Times (South Africa)
  • A once-a-day pill can protect people who inject drugs such as heroin from the AIDS virus, lowering their risk by nearly 50 percent, researchers reported Wednesday.

    June 12, 2013
    NBC News
  • The National Institutes of Health on Thursday halted a study testing an experimental HIV vaccine after an independent review board found the vaccine did not prevent HIV infection and did not reduce the amount of HIV in the blood. "This trial has provided a clear, swift answer about a specific vaccine strategy. It's not the answer we hoped for, but the search doesn't end here," Mitchell Warren, executive director of the nonprofit group AVAC: Global Advocacy for HIV Prevention, said in a statement.

    April 25, 2013
  • For more than 30 years, the belief was that “safer sex = condoms”. But what happens when science shows that pills and gels can also prevent HIV? How do we rethink decades of prevention programs that equated condoms with safer sex and left few other choices?

    April 1, 2013
    ACHIEVE Vol. 5, No. 4
  • About two thirds of women didn’t consistently use Gilead’s daily pill Truvada or Viread, which came in the form of a pill or vaginal gel, according to the study released yesterday at the Conference on Retroviruses and Opportunistic Infections in Atlanta.

    March 5, 2013
    Bloomberg News
  • A three-year clinical trial involving over 5,000 women in East and Southern Africa has found that pre-exposure prophylaxis (PrEP) - whether a vaginal gel or an oral tablet - is not effective at preventing HIV infection in young, unmarried women.

    March 5, 2013
  • The failure was due not to the methods — two different pills and a vaginal gel — but to the fact that the women did not use them consistently.

    March 4, 2013
    New York Times
  • The daily use of a vaginal gel or oral medication does not appear to prevent HIV infection in young, unmarried African women, according to the results of a large HIV prevention trial...

    March 4, 2013
    Mail & Guardian (South Africa)
  • "Perhaps the most important finding was that although women came back to the clinic every month and were dedicated to the trial, the majority of these women didn’t actually take the product in the end."

    March 4, 2013
    Voice of America